Lilly Is Betting On Byetta LAR
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Lechleiter is “confident” that clinical data expected this quarter on Lilly’s follow-on Byetta LAR will overcome FDA concerns over Byetta.
You may also be interested in...
Liraglutide Up For Approval In U.S. And Europe
Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.
Liraglutide Up For Approval In U.S. And Europe
Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.
Amylin CEO: Firm Can Do Better With Byetta
Diabetes drug so far has failed to catch on with primary-care docs.